Jonathan W. Goldman, MD, discusses management of the most common adverse events associated with osimertinib in patients with non–small cell lung cancer.
Jonathan W. Goldman, MD, associate professor of medicine in the hematology/oncology division, director of clinical trials in thoracic oncology, and the associate director of early drug development at UCLA Health, discusses management of the most common adverse events (AEs) associated with osimertinib (Tagrisso) in patients with non–small cell lung cancer.
Goldman says that osimertinib is generally well tolerated compared with other agents in this space. It has less incidence of severe rash than the previously used EGFR inhibitors erlotinib (Tarceva) and gefitinib (Iressa), which osimertinib was compared with in the FLAURA trial (NCT02296125).
Approximately 10% of patients require supportive care for diarrhea; Goldman suggests giving patients loperamide (Imodium) and making sure they have it on hand. Paronychia infecting the skin of the fingers or toes can be another challenge. He says a podiatrist can be consulted for paronychia of the feet and they are often effective at controlling this toxicity. For the hands or in general, patients can manage paronychia with moisturizer, or soak with saltwater Epsom salts. They can also cover the area affected or use ointment such as petroleum jelly.
TRANSCRIPTION:
0:08 | Osimertinib is in general an easy therapy for most patients to tolerate in the metastatic setting.... Compared [with] other EGFR inhibitors, we tend to see less rash and that was really the most significant challenge for most patients on the previous drugs erlotinib or gefitinib, so that was a welcome change.
We still do see diarrhea that needs management in about 10% of patients. There we use typically loperamide for patients and I often ask patients to have it on hand, especially if they're leaving town or something like that, so they're ready to treat that.
0:53 | Paronychia can be challenging, sometimes painful and difficult in some circumstances to completely control. If there's any paronychia of the feet, I do very frequently get a podiatrist involved; they're often very successful at treating it. Of the hands, sometimes not quite the same opportunity to get other specialists involved, but keeping the hands off with a moisturizer, sometimes, saltwater [or] Epsom salt soaks can be helpful; Band-Aids and covering the area if it gets particularly inflamed, and occlusive ointment, as simple as Vaseline or something with antibiotics can be helpful as well. And those are really the most common [AEs] that we see.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More